Cell line licensing for commercial use

Buying a cell line buys you the vial. It does not buy you the right to sell anything you make from it.

That sentence is the whole page. Every repository and vendor agreement examined below grants research use as standard and withholds commercial use as a separate, separately priced, separately negotiated licence. The gap between those two things is where commercial programmes built on purchased cells quietly fail, usually about eighteen months in, when someone in legal finally reads the material transfer agreement that a postdoc clicked through in year one.

The distinction that actually governs your project

Three terms recur across almost every agreement in this market, and getting them straight resolves most of the confusion.

Progeny is an unmodified descendant. ATCC defines it as “an unmodified descendant from the ATCC Original Materials, such as plasmid from plasmid, virus from virus, cell from cell, or organism from organism.” Passaging a line produces progeny. Progeny is treated as the original material and carries all of its restrictions.

Unmodified derivatives are substances native to and characteristic of the original material. ATCC’s list is long and deliberately so: “characteristic nucleic acids, proteins, lipids, carbohydrates, metabolites, membranes, exosomes, organelles, and other native substances, characteristic sequence data … antibodies secreted by a hybridoma cell line, or purified or fractionated subsets or lysates of any of the above.” Note what is in that list. Sequence data. Exosomes. Lysates. If your product is conditioned medium, an exosome preparation, or a sequence, you have not escaped the licence by not shipping cells.

Modifications are things you create that are not progeny or unmodified derivatives but still contain or incorporate the original material. A CRISPR-edited version of a purchased line is a modification. So, in the ordinary reading, is a differentiated cell produced from a purchased iPSC line — the differentiated neuron incorporates the original material’s genome.

That last point is the one buyers most often get wrong. There is a widespread and comfortable assumption that differentiation is transformative enough to break the chain. Nothing in the agreements examined here supports it. The neuron is downstream of the line, and the line’s terms follow it.

What “commercial use” means in the documents themselves

ATCC’s definition is the most explicit published example in this market, and because it is published verbatim it is worth reading rather than paraphrasing. ATCC defines Commercial Use as use of the materials for commercial benefit, “including without limitation”:

1. “for sale, license, lease, export, transfer or other distribution for financial purposes or other commercial purposes”;
2. “to provide a service for financial purposes, including but not limited to proficiency testing, preclinical, clinical, bioproduction/manufacturing services or any other fee-for-service use by a CRO, any university core facility, or any other third-party contractor”;
3. “to produce or manufacture products for general sale or ultimately intended for general sale, including use in a commercial manufacturing process such as fermentation, bioproduction or isolation processes”;
4. “in a clinical trial or other testing regulated by a government agency (e.g. FDA, EMEA, EPA, etc.) or in any human”;
5. “to collect and commercially exploit data regarding sequences of nucleic acids, proteins or other biological polymers, or relative amounts of biological substances or biological activities”; or
6. “to generate a whole or partial genome sequence and use the foregoing for financial purposes.”

Clause 2 is the one that catches service businesses. A university core facility charging recharge rates is named explicitly. Clause 5 catches data businesses that never touch a customer with a cell. Clause 6 catches sequencing.

The operative restriction is short and unambiguous: “ATCC Materials may only be used by Recipient for research purposes and shall not be used for any Commercial Use without first obtaining a Commercial Use license from ATCC.”

Licensing classes compared

The bit.bio row deserves an explicit note because the published documents pull in two directions and a buyer should know that before relying on either. The Limited Use Licence prohibits the User from offering commercial services using the product, while the ordering FAQ states that “ioCells can be purchased by service providers and CROs to provide services to their clients.” Both statements are published by the vendor. The reconciliation is probably that service providers are contemplated but require the upstream TET Systems and ERS Genomics licences named in the same document, and possibly a separate arrangement. We have not confirmed that reading with the vendor. If you are a CRO planning to build a service on these cells, get the position in writing on your own purchase order before you quote a client.

Why the derivative right is the real gate

Consider the ordinary shape of a commercial programme in this field. You buy an iPSC line. You differentiate it into cortical neurons. You plate those neurons onto a device, mature them, and sell the assembly — or you sell an assay service run on them, or you sell the data the assay produces.

Under the terms above, every one of those three exits is a commercial use, and none of them is covered by the purchase.

• Selling the assembly is “sale … or other distribution for financial purposes.”
• Selling the assay service is “to provide a service for financial purposes.”
• Selling the data is, at minimum, collecting and commercially exploiting data regarding “relative amounts of biological substances or biological activities.”

The differentiated neuron is a modification incorporating the original material, so the restriction travels with it. And under ATCC’s terms, modifications “may only be made and used by Recipient in its facility” — which also means you cannot casually hand the differentiation step to a contract manufacturer and treat that as a solved problem. That transfer is itself constrained.

This is why the licence, not the cell price, is the gating cost of a commercial wetware product. A vial of neurons at $643 is a rounding error against a negotiated commercial licence with an upfront fee, an annual fee, a per-unit royalty, and reporting obligations. The catalogue price tells you almost nothing about the cost of your programme.

The layer underneath: patents you are not being sold

Repositories are careful to say that they are not clearing your path. ATCC’s language is direct: materials “shall not be used in any manner that infringes a valid patent in force,” and the “Recipient shall have the sole responsibility for identifying and obtaining any third party licenses required.”

For pluripotent stem cell work this matters more than for most material classes, because the reprogramming methods, the selection systems and the editing tools each carry their own estate. The bit.bio document is unusually transparent about this: it names TET Systems GmbH & Co. KG for the tetracycline-inducible expression system and ERS Genomics Limited for CRISPR, and requires a third-party service provider to hold licences directly from those parties. Most vendors do not name their upstream licensors at all, which does not mean the licensors are absent.

Coriell’s CIRM route handles the same problem differently and more helpfully: its commercial licence “includes pass-through fees for the respective IP/license-holders,” and it will consider credit for stem-cell licences you already hold. That is a bundled clearance model rather than a caveat-emptor model, and it is worth a great deal to a buyer who does not have in-house patent counsel.

Where research use is genuinely sufficient

Not every project needs to solve this. Research use is broad and the restrictions are real but bounded. You are almost certainly fine if all of the following hold:

• The work happens inside your own organisation, in your own facility.
• Nobody outside your organisation pays you for the work, the material, or the data.
• You are not running a regulated trial and nothing goes into a human.
• You are not generating genome sequence for financial purposes.
• You are not operating as a shared core facility or an internal repository redistributing the material to unrelated projects.

Academic laboratories doing publicly funded basic research meet this comfortably. Publishing is fine — ATCC explicitly permits transfer of published modifications for non-commercial use subject to written notification. A company doing genuinely internal, pre-commercial target validation is usually fine too, though the boundary gets uncomfortable the moment the work supports a regulatory filing.

Boundary cases worth naming

A CRO running your assay on your behalf. Under ATCC terms you may transfer modifications and unmodified derivatives to CROs “solely for Non-Commercial Use on Recipient’s projects,” with a written undertaking not to onward-transfer, and a return-or-destroy obligation at project end. If the CRO is charging you a fee to run the service, ATCC’s own guidance is that the CRO “should inquire with ATCC regarding its need for a license.” In practice established CROs hold blanket commercial licences; ask yours to confirm it in writing rather than assuming.

A researcher moving institutions. ATCC permits it only if the original recipient consents and notifies ATCC in writing, and the new institution has its own MTA in place. Taking a modified line with you is not automatic.

Screening. ATCC treats screening as a special case: a for-profit entity performing compound screening for drug discovery needs the screening addendum and an annual fee per subject material, purchasable as item ACS-2103F. Crucially, the addendum states that paying it does not authorise commercial use, including screening performed as a contracted service. This is a narrow permission, not a general one.

Donor consent restrictions. These sit alongside the commercial terms and are enforced independently. EBiSC’s framework passes depositor obligations through to the user, including “specific terms of donor consent.” We have documented at least one commercial line whose donor lineage carries a sequencing restriction on ethical-consent grounds that propagates to downstream products. A restriction of that kind will not appear in a price list and can invalidate a planned experiment after purchase.

Isogenic control pairs. If the mutant and the control come from different sources, they may carry different terms. Confirm both.

What to ask before you commit

Ask these in writing, before the purchase order, and keep the answers with the order:

1. What is the exact use grant that comes with this catalogue price — is it research use only?
2. Am I permitted to differentiate this line and, separately, am I permitted to transfer the differentiated product outside my facility?
3. May I use this material to provide a service to a paying third party? If not, what does the licence that permits it cost?
4. May I sell a product manufactured using this material, or containing cells derived from it? Under what fee structure — upfront, annual, per unit, royalty, or a combination?
5. Are there reach-through claims on inventions I make using this material?
6. Which third-party patents or platform licences do I need that you are not granting?
7. Are there donor consent restrictions, and specifically may I sequence?
8. Does the SKU I am buying appear on any product-restriction list?
9. If I later want commercial rights, is that a negotiation with you or with an upstream depositor?

Question 9 separates a tractable problem from an intractable one. Where the repository can grant commercial rights itself — the ATCC and Coriell models — you have one counterparty and a defined process. Where commercial rights sit with the original depositing laboratory, as under the EBiSC model, you are negotiating with an academic institution that may have no commercial licensing precedent for that line, no incentive to move quickly, and its own upstream obligations. Budget quarters, not weeks.

The practical rule

Choose the line for the licence, not only for the phenotype.

Two lines with identical marker profiles and identical price can differ by a year of negotiation and an unbounded royalty. If a commercial derivative is anywhere in your plan, make licensing a first-round selection criterion alongside subtype and purity, and screen it before you invest in characterisation. Retrofitting a licence onto a programme that has already standardised on a line is the weakest negotiating position available, and the other side knows it.

When we run a sourcing exercise, licensing class is a column in the comparison from the outset, and we will tell you when the cheapest line is the one you should not build on.